Through the transaction, Akoya and Quanterix plan to generate roughly $40M in cost synergies by the end of next year, with ...

Quanterix Corp. agreed to acquire life sciences peer Akoya Biosciences Inc. in an all-stock deal, combining two companies that detect diseases at different stages of progression.

Today, Kent Lake issued a statement related to recent disclosures indicating that Quanterix has officially entered into a Securities Purchase Agreement under which Akoya Biosciences (“Akoya ...

Quanterix sees growth with Akoya acquisition, but rising losses and investor skepticism persist. Explore challenges and ...

Breast, pancreatic, and prostate cancers have a disproportionately higher rate of aggressive tumor grade in the target ...

MARLBOROUGH, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the fourth ...

Akoya Biosciences (AKYA) and SAMBAI announced that Akoya’s PhenoCycler-Fusion system will be the foundational spatial proteomics technology ...

(RTTNews) - Akoya Biosciences, Inc. (AKYA),announced Wednesday that its PhenoCycler-Fusion system has been chosen as the foundational spatial proteomics technology for a groundbreaking cancer ...

Akoya Biosciences (AKYA) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.22 per share a year ago. These ...

Quanterix issued the following statement: Quanterix’s proposed acquisition of Akoya is the result of a rigorous and thorough Board evaluation consistent with its commitment to position the ...

Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery and clinical research. The company offers comprehensive single ...